Compare BridgeBio Pharma Inc (BBIO) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Suncor Energy Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Suncor Energy Inc. trades at $63.2 (market cap $73.34B). The key difference: Suncor Energy Inc. is far larger — about 4.4× BridgeBio Pharma Inc's market cap, and Suncor Energy Inc. pays a 2.72% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SU | |
|---|---|---|
Market Cap | $16.61B | $73.34B |
Sector | Health | Energy |
52-Week High | $90.17 | $69.73 |
52-Week Low | $47.29 | $38.17 |
Enterprise Value | $18.16B | $80.01B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Suncor Energy (SU) trades at $60.1, down 2.04% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.27, beating estimates, and maintains a strong balance sheet with $3.48B in cash. Valuation ratios appear attractive with a P/E of 11.24 and EV/EBITDA of 5.42. Recent news highlights leadership changes, with Peter Zebedee set to become CEO in 2027.
Outlook is mixed: strong cash flow and analyst buy ratings (74% consensus) support upside, but near-term technical weakness and operational challenges from weather impacts pose risks. The stock offers value with solid profitability (ROE 19.25%) but faces volatility from oil price fluctuations and execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
